Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)

Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, and multimodal strategies, such as surgery plus neoadjuvant chemotherapy (NAC)/adjuvant chemotherapy, have been attempted to improve survival in patients with localized PDAC. To date, there is one prospective study prov...

Full description

Bibliographic Details
Main Authors: Daisaku Yamada, Shogo Kobayashi, Hidenori Takahashi, Hirofumi Akita, Terumasa Yamada, Tadafumi Asaoka, Junzo Shimizu, Yutaka Takeda, Shigekazu Yokoyama, Masanori Tsujie, Akira Tomokuni, Masahiro Tanemura, Osakuni Morimoto, Masahiro Murakami, Yongkook Kim, Shin Nakahira, Naoki Hama, Keishi Sugimoto, Kazuhiko Hashimoto, Yuichiro Doki, Hidetoshi Eguchi
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Trials
Subjects:
Pancreatic cancer
Neoadjuvant chemotherapy
Gemcitabine plus S-1
Gemcitabine plus nab-paclitaxel
Online Access:https://doi.org/10.1186/s13063-021-05541-w

Internet

https://doi.org/10.1186/s13063-021-05541-w

Similar Items